Studies related to Atherosclerosis and Ginkgo biloba

Reduction Of Atherosclerotic Nanoplaque Formation And Size By Ginkgo Biloba (EGb 761) In Cardiovascular High-risk Patients

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 8
Sex Both Genders
Age Range 18-29, 30-44
Body Types Overweight
Notes for this study:
Two months supplementation of 120mg EGb-761 twice daily is able to reduce the oxidation of LDL and improve antioxidant status while also improving biomarkers of blood flow (cGMP) and reducing artherosclerotic buildup.

Both superoxide dismutase and glutathione peroxidase were increased as well as cAMP, and IL-6 as well as myeloperoxidase were reduced.